Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
GlaxoSmithKline |
---|---|
Information provided by: | GlaxoSmithKline |
ClinicalTrials.gov Identifier: | NCT00324961 |
This is a phase IV, 2-year, multi-center, single arm and open-label study, evaluating the efficacy and safety with using local manufactured adefovir dipivoxil in Chinese subjects with HBeAg negative chronic hepatitis B
Condition | Intervention | Phase |
---|---|---|
Chronic Hepatitis B |
Drug: adefovir dipivoxil tablets |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Single Group Assignment, Safety/Efficacy Study |
Official Title: | A 2-Year Multi-Centre, Open-Label, Local Phase IV Study to Demonstrate the Efficacy and Safety of Adefovir Dipivoxil Tablets (10mg) in Chinese Subjects With HBe Antigen Negative Chronic Hepatitis B |
Enrollment: | 533 |
Study Start Date: | January 2006 |
Study Completion Date: | January 2009 |
Primary Completion Date: | January 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
Single arm open label adefovir dipivoxil: Experimental
adefovir dipivoxil once daily 10 mg orally
|
Drug: adefovir dipivoxil tablets
adefovir dipivoxil once daily 10 mg orally
|
Ages Eligible for Study: | 18 Years to 65 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Compensated liver disease with the following laboratory and clinical parameters at study screening:
A female is eligible to enter and participate in this study if she is of:
Exclusion Criteria:
serum bilirubin > 2.5 mg/dL (≤ 43 µmol/L)
history of ascites, variceal bleeding, or encephalopathy
- where no positive ultrasound finding, but serum alpha-fetoprotein > 100ng/mL
China | |
GSK Investigational Site | |
Beijing, China, 100044 | |
GSK Investigational Site | |
Changsha, China, 410008 | |
GSK Investigational Site | |
Shanghai, China, 200040 | |
GSK Investigational Site | |
Beijing, China, 100050 | |
GSK Investigational Site | |
Shanghai, China, 200433 | |
GSK Investigational Site | |
Beijing, China, 100011 | |
GSK Investigational Site | |
Chongqing, China, 400038 | |
GSK Investigational Site | |
Shanghai, China, 200025 | |
GSK Investigational Site | |
Jinan, China, 250021 | |
GSK Investigational Site | |
Chongquin, China, 400038 | |
GSK Investigational Site | |
Shanghai, China, 200003 | |
GSK Investigational Site | |
Shanghai, China, 200001 | |
China, Guangdong | |
GSK Investigational Site | |
Guangzhou, Guangdong, China, 510515 | |
GSK Investigational Site | |
Guangzhou, Guangdong, China, 510630 | |
China, Hubei | |
GSK Investigational Site | |
Wuhan, Hubei, China, 430030 | |
China, Jiangsu | |
GSK Investigational Site | |
Nanjing, Jiangsu, China, 210029 | |
China, Jilin | |
GSK Investigational Site | |
Changchun, Jilin, China, 130021 | |
China, Zhejiang | |
GSK Investigational Site | |
Hangzhou, Zhejiang, China, 310003 |
Study Director: | GSK Clinical Trials | GlaxoSmithKline |
Responsible Party: | GSK ( Study Director ) |
Study ID Numbers: | ADF106632 |
Study First Received: | May 9, 2006 |
Last Updated: | March 26, 2009 |
ClinicalTrials.gov Identifier: | NCT00324961 History of Changes |
Health Authority: | China: State Food and Drug Administration |
adefovir dipivoxil e Antigen negative chronic hepatitis B Chinese |
Anti-Infective Agents Liver Diseases Hepatitis, Chronic Hepatitis, Viral, Human Antiviral Agents Reverse Transcriptase Inhibitors Hepatitis Virus Diseases |
Digestive System Diseases Anti-Retroviral Agents Hepatitis B, Chronic Hepatitis B DNA Virus Infections Adefovir dipivoxil Adefovir |
Anti-Infective Agents Liver Diseases Molecular Mechanisms of Pharmacological Action Hepatitis, Chronic Hepatitis, Viral, Human Enzyme Inhibitors Hepadnaviridae Infections Antiviral Agents Pharmacologic Actions Reverse Transcriptase Inhibitors Hepatitis |
Virus Diseases Digestive System Diseases Anti-Retroviral Agents Therapeutic Uses Hepatitis B, Chronic Hepatitis B DNA Virus Infections Adefovir dipivoxil Adefovir Nucleic Acid Synthesis Inhibitors |